Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q7Z3V4

UPID:
UBE3B_HUMAN

ALTERNATIVE NAMES:
HECT-type ubiquitin transferase E3B

ALTERNATIVE UPACC:
Q7Z3V4; A5D8Z3; Q05BX9; Q659F7; Q7Z7Q1; Q9BXZ4

BACKGROUND:
The Ubiquitin-protein ligase E3B, known alternatively as HECT-type ubiquitin transferase E3B, is integral to the ubiquitination pathway, affecting numerous cellular processes including protein turnover and cellular signaling. This enzyme facilitates the final step of ubiquitin transfer, marking proteins for degradation or functional modification.

THERAPEUTIC SIGNIFICANCE:
Linked to Kaufman oculocerebrofacial syndrome, characterized by severe developmental and physical abnormalities, the study of Ubiquitin-protein ligase E3B offers a promising avenue for therapeutic intervention. Understanding its role could lead to breakthroughs in treatment strategies for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.